Taysha Gene Therapies, Inc.
TSHA
$1.24
$0.065.09%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -46.07% | -30.90% | 34.05% | 96.39% | 517.55% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -46.07% | -30.90% | 34.05% | 96.39% | 517.55% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -46.07% | -30.90% | 34.05% | 96.39% | 517.55% |
| SG&A Expenses | -3.47% | -14.05% | -9.42% | -20.75% | -22.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.36% | 5.63% | -2.83% | -6.83% | -32.45% |
| Operating Income | -21.36% | -12.80% | 7.10% | 14.84% | 43.37% |
| Income Before Tax | 19.96% | 89.38% | 7.66% | 11.49% | 32.80% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 19.96% | 89.38% | 7.66% | 11.49% | 32.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.96% | 89.38% | 7.66% | 11.49% | 32.80% |
| EBIT | -21.36% | -12.80% | 7.10% | 14.84% | 43.37% |
| EBITDA | -21.96% | -13.13% | 7.25% | 15.17% | 43.93% |
| EPS Basic | 73.71% | 97.57% | 60.69% | 56.71% | 63.97% |
| Normalized Basic EPS | 75.19% | 98.43% | 46.39% | 44.09% | 57.01% |
| EPS Diluted | 73.71% | 97.57% | 60.69% | 56.71% | 63.97% |
| Normalized Diluted EPS | 75.19% | 98.43% | 46.39% | 44.09% | 57.01% |
| Average Basic Shares Outstanding | 115.67% | 204.43% | 255.99% | 214.75% | 164.06% |
| Average Diluted Shares Outstanding | 115.67% | 204.43% | 255.99% | 214.75% | 164.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |